[
  {
    "ts": null,
    "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
    "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
    "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757962258,
      "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
      "id": 136767795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428756484/image_1428756484.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
      "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182"
    }
  },
  {
    "ts": null,
    "headline": "REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?",
    "summary": "Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.",
    "url": "https://finnhub.io/api/news?id=26fa08c3b77dd6db0a81984e77f245c35f69c9267bf899b77cc7f54dcb3d7e30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757947980,
      "headline": "REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?",
      "id": 136766090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.",
      "url": "https://finnhub.io/api/news?id=26fa08c3b77dd6db0a81984e77f245c35f69c9267bf899b77cc7f54dcb3d7e30"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640. The analyst noted that his rating is based on the strong results from Phase 3 […]",
    "url": "https://finnhub.io/api/news?id=f21c6760eb6e618bba522c59b094b95fde886d9c2861742f52ffcc5429fb5852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757942129,
      "headline": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)",
      "id": 136749751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640. The analyst noted that his rating is based on the strong results from Phase 3 […]",
      "url": "https://finnhub.io/api/news?id=f21c6760eb6e618bba522c59b094b95fde886d9c2861742f52ffcc5429fb5852"
    }
  }
]